Many Medicare Advantage plans send caregivers to the homes of seniors periodically to help with housework and provide companionship. But the workers may also prod seniors into activities that boost the plans’ Medicare ratings and federal reimbursements.
Membership-based villages help arrange services for seniors — such as handyman help or transportation to appointments — and provide social connections through classes, leisure opportunities, or community events. Despite great promise, they have been slow to expand because of difficulties raising funding and keeping people interested.
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
CMS chief Chiquita Brooks-LaSure says the agency reserves its power to quickly institute new regulations for “absolute emergencies.” On staffing, nursing home residents might need to wait years to see any real change.
The president wants to set minimum staffing levels for the beleaguered industry, but the industry’s opaque finances make it a mystery how homes will shoulder the added costs.
KHN gives readers a chance to comment on a recent batch of stories.
Nine seniors from across the country talk frankly about feeling alone and constrained, missing church, and family routines. They also share newfound hope and discoveries that arose from the crisis.
The spread of the omicron variant has dashed the hopes of many older adults that the country was exiting the worst of the pandemic, leaving them anxious while their patience wears thin.
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of “PDUFA” also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimer’s disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
